3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 12 février 2020
Doi : 10.1016/j.jaad.2019.09.032
accepted : 17 September 2019
Pyoderma gangrenosum in hematologic malignancies: A systematic review

Carmen M. Montagnon, MD a, Elizabeth A. Fracica, MD, MPH b, Archna A. Patel, BS c, Michael J. Camilleri, MD d, M. Hassan Murad, MD, MPH e, David Dingli, MD, PhD f, David A. Wetter, MD d, Stanislav N. Tolkachjov, MD g,
a Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 
b Johns Hopkins Bayview Medical Center, Baltimore, Maryland 
c Alix School of Medicine, Mayo Clinic, Rochester, Minnesota 
d Department of Dermatology, Mayo Clinic, Rochester, Minnesota 
e Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota 
f Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 
g Epiphany Dermatology, Dallas, Texas 

Reprint requests: Stanislav N. Tolkachjov, MD, Epiphany Dermatology, 9191 Kyser Way, Bldg 3, Frisco, TX 75033.Epiphany Dermatology9191 Kyser WayBldg 3FriscoTX75033

Pyoderma gangrenosum (PG) is a devastating neutrophilic dermatosis that may be associated with trauma or systemic diseases. The associations, characteristics, and temporal relationship of PG with hematologic malignancies are not well understood.


We performed a systematic review of PG associated with hematologic malignancies using data from case reports, case series, and retrospective studies.


We searched MEDLINE, EMBASE, Scopus, and Web of Science from each database's inception to December 12, 2018. Two reviewers independently selected studies and extracted data.


Two hundred seventy-nine publications met the inclusion criteria (340 cases). Myelodysplastic syndrome (MDS) was the most commonly reported hematologic malignancy associated with PG, followed by monoclonal gammopathy of undetermined significance and acute myeloid leukemia. The mean age of patients was 56.5 years, with males being more common. There was a predominance of the ulcerative PG subtype and multifocal distributions across all hematologic malignancies. The majority of MDS cases preceded PG, which was reversed for MGUS.


The data were limited by reporting bias because PG subtypes rely on the rendered diagnosis reported. In addition, the classification for hematologic malignancies has evolved since 1978.


Patients with PG should be evaluated for hematologic malignancies, with MDS being the most common.

The full text of this article is available in PDF format.

Key words : blood, gammopathy, gangrenosum, hematology, leukemia, lymphoma, myelodysplastic, myeloid, pyoderma, ulcer

Abbreviations used : AML, IL, MGUS, ND, PG

 Funding sources: None
 Conflicts of interest: None declared.
 Presented as an ePoster at the American Academy of Dermatology 2019 Annual Meeting, Washington, DC, March 1-5, 2019.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline